See Also:
HWCI Research Associate Program
Submissions from 2026
The hematology workforce in the United States: past, present, and strategies for the future, Srikanth Nagalla
The Ki-67 proliferation index and recurrence risk of intracranial meningioma: a multicenter, retrospective cohort study of 5,050 patients, Michael McDermott
The Miami Cancer Institute technique: Puboprostatic complex preserving dorsal venous complex ligation with cystourethropexy, Deerush Kannan Sakthivel, Pushan Prabhakar, Mohamed Javid Raja Iyub, Arjun Pon Avudaiappan, and Murugesan Manoharan
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0, Bruna Pellini
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1, Bruna Pellini
The Role of Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Carcinoma in the Era of Emerging Systemic Therapy: A Retrospective Cohort Study, Mohammad Arfat Ganiyani, Arjun Pon Avudaiappan, Mohamed Javid Raja Iyub, Murugesan Manoharan, and Rohan Garje
Three-Arm Versus Four-Arm Configurations in Robot-Assisted Partial Nephrectomy: A Systematic Review and Meta-Analysis, Mohamed Javid Raja Iyub, Pushan Prabhakar, Deerush Kannan Sakthivel, Manuel Ozambela, and Murugesan Manoharan
Time Course and Determinants of Acute Dysgeusia in Patients Receiving Head and Neck Radiation Therapy, Sreenija Yarlagadda, Arun Maharaj, Andrea Gonzalez, NaimaSajoni Guerra, Dylan Paterniti-Ruscin, Elysse Castro-Hall, Lorein Gonzalez, Muni Rubens, Noah Kalman, and Adeel Kaiser
TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab, Sarbajit Mukherjee
TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab, Sarbajit Mukherjee
Treating brainstem metastases with stereotactic radiosurgery after whole-brain radiotherapy - precision strike or risky gamble?, D. Jay Wieczorek and Rupesh Kotecha
Treatment deintensification in average-risk medulloblastoma: Less is more?, Matthew Hall
Treatment-free survival with first-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: a critical analysis beyond PD-L1 expression, Zouina Sarfraz and Manmeet Ahluwalia
Treatment patterns and survival outcomes in neuroendocrine neoplasms presenting with brain metastases, Zouina Sarfraz, Fatma Akkoc Mustafayev, Lydia Hodgson, and Manmeet Ahluwalia
Trends in preferred place of death among patients with bladder cancer in the United States, 2000 to 2020, Mohammad Arfat Ganiyani and Rohan Garje
Tumor Treating Fields Therapy After Stereotactic Radiosurgery for Brain Metastases From Non-Small Cell Lung Cancer: Final Results of the Phase 3 METIS Study, Minesh Mehta and Manmeet Ahluwalia
Uncommon Encounter in Urachus: A Rare Case of Xanthogranulomatous Urachitis With Review of Literature, Mohamed Javid Raja Iyub
Understanding the Promise and Challenges of Tumor-Agnostic Therapy: Could One Size Really Fit All?, Manmeet Ahluwalia, Sarbajit Mukherjee, and Kyaw Aung
Use of Absorbable Antibiotic Delivery Beads in Implant-Based Breast Reconstruction, Aneeq Chaudhry, Rita Quintana, Neriah Bethel, David Mattos, Harry Salinas, Matthew Treiser, and Miguel Medina
Submissions from 2025
Evaluation of Hepatorenal Syndrome Therapy in Hospitalized Patients, Christian Hu, Maricela Moreno Martinez, Riley Christian, Heidi Clarke, and Jonathan Kline
Evaluation of Von Willebrand Factor Product Use Across an Acute Care Health-Care System, Kyle Eilert, Gladimarys Grajales Aviles, Maria Ruiz, Radhan Gopalani, Erika Dittmar, and Estela Trimino